Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 134

1.

Mice lacking bone sialoprotein (BSP) lose bone after ovariectomy and display skeletal site-specific response to intermittent PTH treatment.

Wade-Gueye NM, Boudiffa M, Laroche N, Vanden-Bossche A, Fournier C, Aubin JE, Vico L, Lafage-Proust MH, Malaval L.

Endocrinology. 2010 Nov;151(11):5103-13. doi: 10.1210/en.2010-0091. Epub 2010 Sep 15.

PMID:
20844009
[PubMed - indexed for MEDLINE]
2.

Absence of bone sialoprotein (BSP) impairs primary bone formation and resorption: the marrow ablation model under PTH challenge.

Wade-Gueye NM, Boudiffa M, Vanden-Bossche A, Laroche N, Aubin JE, Vico L, Lafage-Proust MH, Malaval L.

Bone. 2012 May;50(5):1064-73.

PMID:
22586700
[PubMed - indexed for MEDLINE]
3.

Anabolic action of parathyroid hormone is skeletal site specific at the tissue and cellular levels in mice.

Iida-Klein A, Zhou H, Lu SS, Levine LR, Ducayen-Knowles M, Dempster DW, Nieves J, Lindsay R.

J Bone Miner Res. 2002 May;17(5):808-16.

PMID:
12009011
[PubMed - indexed for MEDLINE]
4.

Accentuated osteoclastic response to parathyroid hormone undermines bone mass acquisition in osteonectin-null mice.

Machado do Reis L, Kessler CB, Adams DJ, Lorenzo J, Jorgetti V, Delany AM.

Bone. 2008 Aug;43(2):264-73. doi: 10.1016/j.bone.2008.03.024. Epub 2008 Apr 13.

PMID:
18499553
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Mice lacking AMP-activated protein kinase α1 catalytic subunit have increased bone remodelling and modified skeletal responses to hormonal challenges induced by ovariectomy and intermittent PTH treatment.

Jeyabalan J, Shah M, Viollet B, Roux JP, Chavassieux P, Korbonits M, Chenu C.

J Endocrinol. 2012 Sep;214(3):349-58. doi: 10.1530/JOE-12-0184. Epub 2012 Jun 14.

PMID:
22700192
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

The anabolic action of intermittent PTH in combination with cathepsin K inhibitor or alendronate differs depending on the remodeling status in bone in ovariectomized mice.

Yamane H, Sakai A, Mori T, Tanaka S, Moridera K, Nakamura T.

Bone. 2009 Jun;44(6):1055-62. doi: 10.1016/j.bone.2008.05.010. Epub 2008 May 23.

PMID:
19303837
[PubMed - indexed for MEDLINE]
7.

Basal bone phenotype and increased anabolic responses to intermittent parathyroid hormone in healthy male COX-2 knockout mice.

Xu M, Choudhary S, Voznesensky O, Gao Q, Adams D, Diaz-Doran V, Wu Q, Goltzman D, Raisz LG, Pilbeam CC.

Bone. 2010 Aug;47(2):341-52. doi: 10.1016/j.bone.2010.05.006. Epub 2010 May 13.

PMID:
20471507
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Beta-Arrestin2 regulates RANKL and ephrins gene expression in response to bone remodeling in mice.

Pierroz DD, Rufo A, Bianchi EN, Glatt V, Capulli M, Rucci N, Cavat F, Rizzoli R, Teti A, Bouxsein ML, Ferrari SL.

J Bone Miner Res. 2009 May;24(5):775-84. doi: 10.1359/jbmr.081237.

PMID:
19113915
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Parathyroid hormone (PTH)/PTH-related peptide type 1 receptor (PPR) signaling in osteocytes regulates anabolic and catabolic skeletal responses to PTH.

Saini V, Marengi DA, Barry KJ, Fulzele KS, Heiden E, Liu X, Dedic C, Maeda A, Lotinun S, Baron R, Pajevic PD.

J Biol Chem. 2013 Jul 12;288(28):20122-34. doi: 10.1074/jbc.M112.441360. Epub 2013 Jun 2.

PMID:
23729679
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Differential transcriptional effects of PTH and estrogen during anabolic bone formation.

von Stechow D, Zurakowski D, Pettit AR, Müller R, Gronowicz G, Chorev M, Otu H, Libermann T, Alexander JM.

J Cell Biochem. 2004 Oct 15;93(3):476-90.

PMID:
15372627
[PubMed - indexed for MEDLINE]
11.

Bone response to intermittent parathyroid hormone is altered in mice null for {beta}-Arrestin2.

Ferrari SL, Pierroz DD, Glatt V, Goddard DS, Bianchi EN, Lin FT, Manen D, Bouxsein ML.

Endocrinology. 2005 Apr;146(4):1854-62. Epub 2005 Feb 10.

PMID:
15705780
[PubMed - indexed for MEDLINE]
12.

Are osteoclasts needed for the bone anabolic response to parathyroid hormone? A study of intermittent parathyroid hormone with denosumab or alendronate in knock-in mice expressing humanized RANKL.

Pierroz DD, Bonnet N, Baldock PA, Ominsky MS, Stolina M, Kostenuik PJ, Ferrari SL.

J Biol Chem. 2010 Sep 3;285(36):28164-73. doi: 10.1074/jbc.M110.101964. Epub 2010 Jun 17.

PMID:
20558734
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Combined treatment with a beta-blocker and intermittent PTH improves bone mass and microarchitecture in ovariectomized mice.

Pierroz DD, Bouxsein ML, Rizzoli R, Ferrari SL.

Bone. 2006 Aug;39(2):260-7. Epub 2006 Mar 10.

PMID:
16531131
[PubMed - indexed for MEDLINE]
14.

Biglycan deficiency interferes with ovariectomy-induced bone loss.

Nielsen KL, Allen MR, Bloomfield SA, Andersen TL, Chen XD, Poulsen HS, Young MF, Heegaard AM.

J Bone Miner Res. 2003 Dec;18(12):2152-8.

PMID:
14672350
[PubMed - indexed for MEDLINE]
15.

The anabolic response to parathyroid hormone is augmented in Rac2 knockout mice.

Kawano T, Troiano N, Adams DJ, Wu JJ, Sun BH, Insogna K.

Endocrinology. 2008 Aug;149(8):4009-15. doi: 10.1210/en.2008-0034. Epub 2008 May 8.

PMID:
18467443
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

The skeleton in primary hyperparathyroidism: a review focusing on bone remodeling, structure, mass, and fracture.

Christiansen P.

APMIS Suppl. 2001;(102):1-52. Review.

PMID:
11419022
[PubMed - indexed for MEDLINE]
17.

Continuous parathyroid hormone and estrogen administration increases vertebral cancellous bone volume and cortical width in the estrogen-deficient rat.

Zhou H, Shen V, Dempster DW, Lindsay R.

J Bone Miner Res. 2001 Jul;16(7):1300-7.

PMID:
11450706
[PubMed - indexed for MEDLINE]
18.

The calcium-sensing receptor complements parathyroid hormone-induced bone turnover in discrete skeletal compartments in mice.

Xue Y, Xiao Y, Liu J, Karaplis AC, Pollak MR, Brown EM, Miao D, Goltzman D.

Am J Physiol Endocrinol Metab. 2012 Apr 1;302(7):E841-51. doi: 10.1152/ajpendo.00599.2011. Epub 2012 Jan 24.

PMID:
22275754
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Disruption of LRP6 in osteoblasts blunts the bone anabolic activity of PTH.

Li C, Xing Q, Yu B, Xie H, Wang W, Shi C, Crane JL, Cao X, Wan M.

J Bone Miner Res. 2013 Oct;28(10):2094-108. doi: 10.1002/jbmr.1962.

PMID:
23609180
[PubMed - indexed for MEDLINE]
20.

Overexpression of bone sialoprotein leads to an uncoupling of bone formation and bone resorption in mice.

Valverde P, Zhang J, Fix A, Zhu J, Ma W, Tu Q, Chen J.

J Bone Miner Res. 2008 Nov;23(11):1775-88. doi: 10.1359/jbmr.080605.

PMID:
18597627
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk